- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.02. | Compass, with Phase 3 hits, ready to take psilocybin to the FDA | ||
| 17.02. | Ocular claims a win with Phase 3 eye drug data even as shares sink | ||
| 17.02. | Selecting the optimal cell therapy manufacturing platform | ||
| 17.02. | How to evaluate prospective diagnostic laboratory partners for your patient support program | ||
| 13.02. | Vertex's CRISPR therapy rebounds in latest earnings | ||
| 13.02. | Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs | ||
| 13.02. | Ultragenyx cuts jobs as it seeks path to profit in 2027 | ||
| 13.02. | Moderna shares jump as company affirms growth outlook | ||
| 13.02. | FDA removes box warning for 6 menopausal therapies | ||
| 12.02. | Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor | ||
| 12.02. | Seres to lay off staff, pause top program in latest reboot | ||
| 12.02. | Lowering drug costs is on Republicans' minds. Democrats say GOP policies don't help. | ||
| 12.02. | Sanofi, looking for more 'rigor,' swaps CEO Hudson for ex-Merck KGaA chief Garijo | ||
| 12.02. | BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis | ||
| 11.02. | CDC moves to cut $600M in grants to Democrat-led states | ||
| 11.02. | Madrigal turns to RNAi drugs from China to bolster MASH pipeline | ||
| 11.02. | Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill | ||
| 11.02. | FDA refuses to review Moderna's mRNA flu vaccine | ||
| 10.02. | Nektar, continuing comeback, says eczema drug's effects hold up in follow-up study | ||
| 10.02. | FDA rejects Regenxbio treatment in another blow to gene therapy | ||
| 09.02. | Lilly buys 'in vivo' CAR-T maker Orna, extending streak of genetic medicine deals | ||
| 09.02. | Lilly bets again on China drugs; Roche showcases MS data | ||
| 09.02. | Takeda, Iambic partner in latest pharma AI push | ||
| 09.02. | Navigating the complexities of Cell and Gene Therapy supply chains | ||
| 09.02. | Small and mighty: single-domain antibodies pack a biological punch |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.